A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following symptoms or conditions are excluded:
• •Significant psychosis or emotional disorder that would preclude study compliance.
• •Severe chronic diarrhea (e.g., \> five stools/day) that may negatively affect absorption of oral medication.
• •Unable to take oral medication or unable or unwilling to take medication with food.
• •Concurrent Medication:
• •Excluded:
• •Rifampin.
• •Other investigational agents except for drugs available through Treatment INDs or expanded access programs.
• •Medications likely to have anti-pneumocystis effect (e.g., dapsone, trimethoprim, pyrimethamine, trimetrexate, other DHFR inhibitors, sulfadiazine, sulfamethoxazole, other sulfonamides, primaquine, clindamycin, and sulfonylureas.
• •Corticosteroids in greater than physiologic replacement doses for more than 21 consecutive days.
• •Systemic therapy for CNS toxoplasmosis, Kaposi's sarcoma, lymphoma, other active malignancies, or other disease that may decrease life expectancy or confound assessment.
• •Patients with the following prior conditions are excluded:
• •History of severe or intractable intolerance to atovaquone or aerosolized pentamidine.
• •Prior hypoglycemia, pancreatitis, arrhythmias, or severe hypotension associated with any form of pentamidine.
• •Prior enrollment in this protocol. Active substance abuse that would preclude study compliance.